Drug intelligence / Profile preview

UCT-03-008

Development stage: Phase 1
Lead developer: 1200 Pharma
Modality: Small Molecules
Administration: Oral

Overview

UCT-03-008 is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6), developed by 1200 Pharma for the treatment of advanced solid tumors. By inhibiting CDK4 and CDK6, key regulators of cell cycle progression from G1 to S phase, the drug aims to block tumor cell proliferation and exert antineoplastic effects. As of early 2025, it is in Phase I clinical trials for patients with advanced or late-stage solid malignancies[1][2][3][4][7].

Targets

CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)

Beyond the preview

Go deeper on UCT-03-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UCT-03-008.